New Psychoactive Substances. a Challenge to Public Health
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A. -
Ormond Beach Daytona Beach Holly Hill Your Own
GROW INSIDE ORMOND BEACH DAYTONA BEACH HOLLY HILL YOUR OWN In Garden Nook: Orchids not that hard Page A13 Vol. 6, No. 31 Your Local News and Information Source • www.HometownNewsOL.com Friday, Aug. 26, 2011 Community New state laws mean less You can earn money from home talking about what you already know! If you feel like you Notes are an expert on anything, sign up start earning money as a FREE oversight for local development Broadcaster!and Dance clinic planned • STREAM & SELL YOUR VIDEOS • STREAM AND SELL YOUR LIVE EVENTS By John Bozzo Mr. Goss said this will mean less is what local govern- • VIDEOS ON DEMAND ENCORE Baton & Dance For Hometown News paperwork but more responsibility ments use to regu- studio in Holly Hill will hold Also Offering Videos on Demand for local officials, who are still sort- late land use within Sell your event or educational videos online. a free show and clinic from ORMOND BEACH — With slides ing out what the new law means their cities. They 9:30 a.m. to noon, Saturday, projected on a screen in a small and how decisions in one commu- are used to plan for Aug. 27. No experience is room, the City Commission recent- nity will impact a neighboring the needs of the SIGN UP FOR FREE! necessary. ly studied what responsibilities a community. communities and WWW.HDBroadcasters.COM For more information new state law on growth and urban While many believe the relax- to protect natural about this free clinic, call planning will place in their hands. -
Download Book Sacred Journeys As
Sa cred Jour neys: ©2015, 2016, 2017 Artscience Im ages: authors and friends, com pany and press pic- tures, PhotoDisc, Corel, Wikipedia, Mindlift Beeldbankiers. Dis tri bu tion: Boekencoöperatie Nederland u.a. email: [email protected] www.boekcoop.nl www.boekenroute.nl (webshop) All rights re served, in clud ing dig i tal re dis tri bu tion and ebook First editiion: De cem ber 2015, Sec ond, ap pended edition April 2016 Third edition Jan. 2017 ISBN 9789492079091 pub lisher: Onderstroomboven Collectief im print: Artscience. Pa perback price € 6,95 Con tents 1 Pre fa ce 7 2 Tripping: the process 10 Journey to the dream 10 The pre pa ra ti on 11 Pha ses, gig gling 13 Iso la ti on, li mi na li ty, the dark 14 Peak 19 Sit ters: de sig na ted hel pers 22 The mys ti cal, re gres si on 26 Rebirth and de ath 27 The end of the trip: co ming down 28 Over sti mu la ti on 29 The af ter-ef fects 30 3 Set and Set ting 32 Agen da 33 Pla ce 34 With whom, with what? 34 Bon ding and trans fe ren ce 35 Dif fe rent ways of using 36 4 Pur po se 37 Dee per goals 38 Over co ming fear 40 To le ran ce 41 5 Ri tu als and Group ses sions 42 He a ling jour neys, mys ti cal in sights 44 Me di cal use 45 Re pe ti ti on, loops 46 Stages of a ritu al 49 Ri tes of pas sa ge: ini ti a ti on 50 Contact – alignment - group mind 52 Struc tu re amidst cha os 54 To copy an existing ritu al or to crea te somet hing new 54 6 Sanc tu a ry, safe spa ce 57 Sa fe ty first 57 Sa cred spa ce, tem po ra ry au to no mous zone 58 Hol ding spa ce and cir cle in te gri ty 61 7 His to ry -
Programme & Abstracts
The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday. -
Ecstasy Or Molly, Is a Synthetic Psychoactive Drug
DRUG ENFORCEMENT ADMINISTRATION THE FACTS ABOUT MDMA Ecstasy &Molly DEA PHOTO What is it? MDMA, (3,4-methylenedioxy- methamphetamine), known as Ecstasy or Molly, is a synthetic psychoactive drug. Ecstasy is the pill form of MDMA. Molly is the slang for “molecular” that refers to the powder or crystal form of MDMA. Molly is often mixed with other drugs and substances and is not pure MDMA or safe to use. How is it used? MDMA or Ecstasy is taken orally in pill or tablet form. These pills can be in different colors with images on them. Molly is taken in a gel capsule or snorted. What does MDMA do to the body and mind? • As a stimulant drug, it increases heart rate and blood pressure. Users may experience muscle tension, involuntary teeth clenching, nausea, blurred vision, faintness, chills, or sweating • It produces feelings of increased energy, euphoria, emotional warmth, empathy, and distortions in sensory and time perception. • Feelings of sadness, anxiety, depression and memory difficulties are other effects. • It can seriously deplete serotonin levels in the brain, causing confusion and sleep problems. Did you know? • DEA has labeled MDMA as a Schedule I drug, meaning its abuse potential is high and it has no approved medical use. It is illegal in the U.S. • In high doses, MDMA can affect the body’s ability to regulate temperature, which can lead to serious health complications and possible death. • Teens are using less MDMA. Teens decreased their past year use of MDMA from 1.9% in 2010 to 1.2% of teens using 2012. -
Psychoactive Substances and Transpersonal States
TRANSPERSONAL PSYCHOLOGY RESEARCH REVIEW: PSYCHOACTIVE SUBSTANCES AND TRANSPERSONAL STATES David Lukoff San Francisco, California Robert Zanger Los Angeles, California Francis Lu San Francisco, California This "Research Review" covers recent trends in researching psychoactive substances and trans personal states of conscious ness during the past ten years. In keeping with the stated goals of this section of the Journal to promote research in transpersonal psychology, the focus is on the methods and trends designs which are being employed in investigations rather than during the findings on this topic. However, some recently published the books and monographs provide good summaries of the recent last findings relevant to understanding psychoactive substances ten (Cohen & Krippner, 1985b; Dobkin de Rios, 1984;Dobkin de years Rios & Winkelman, 1989b; Ratsch, 1990; Reidlinger, 1990). Because researching psychoactive substances is most broadly a cross-disciplinary venture, only a small portion of the research reviewed below was conducted by persons who consider The authors wish to acknowledge the assistance of Bruce Flath, head librarian at the California Institute of Integral Studies, San Francisco in conducting the computer bibliographic searches used in preparation of this article. The authors also wish to thank Marlene Dobkin de Rios, Stanley Krippner, Christel Lukoff, Dennis McKenna, Terence McKenna, Ralph Metzner, Donald Rothberg and Ilene Serlin for their valuable comments on earlier drafts of this article. Copyright © 1990 Transpersonal Institute The Journal of Transpersonal Psychology. 1990, Vol. 22, No.2 107 themselves transpersonal psychologists. As Vaughan (1984) has noted, "The transpersonal perspective is a meta-perspec tive, an attempt to learn from all different disciplines . emerging from the needed integration of ancient wisdom and modern science. -
10 Facts About MDMA
10 Facts About MDMA August 2015 1. What is MDMA? and a desire to intensify these feelings by dancing, talking and touching. MDMA, often referred to as “ecstasy” or “molly”, is short for 3,4 methylenedioxymethamphetamine, a A typical dose of 80 - 125 mg lasts three to six hours. psychoactive drug derived from safrole oil. MDMA Some people experience nausea at the outset, but produces effects that resemble both stimulants and after about 45 minutes, report feelings of relaxation psychedelics, as well as its signature effect: a feeling and clarity. MDMA also causes dilation of the pupils of connectedness. It impacts brain function primarily and, often, sensitivity to light, as well as possible jaw- releasing the neurotransmitter serotonin, and also clenching, tooth-grinding, muscle tension, faintness, temporarily inhibits its reuptake. MDMA is usually and chills or sweating. taken orally, whether in pressed pill form, powder or crystal; or sometimes snorted. After the drug wears off, the theory from preclinical studies is that brain levels of serotonin (a chemical MDMA was originally synthesized in 1912 by the drug responsible for maintaining mood balance) are company Merck.1 However, its psychoactive effects depleted, which can lead in some cases to sadness, weren’t widely discovered until 1976 when Alexander anxiety, depression and sleep problems.4 If they occur, Shulgin developed a new synthesis method, tested the these symptoms arise in the several days that follow. drug on himself, and shared it with a few friendly Generally, they abate within a week, though frequency psychotherapists.2 Because of the drug’s effects of of use and higher doses can slow or stop this increasing empathy and reducing fear, it started to be process.5 used in psychotherapy practices in the 1970s and early 80s, as well as recreationally. -
Prohibited Chemical Cn Ver4.00.Xlsx
修订日:2021/7/15 Nitto集团 禁止含有的化学物质 Ver 4.00 分析 备注 物质 化学物质或物质群 阈值 数据 (记载的法律法规只用于对象物质的特定, 例举表 要否 其适用范围不作参考) (不使用保证书中收录的物质) EU REACH法规 AnnexⅩⅦ 未有意添加,且含量不超过1000ppm(不包 石棉类 需要 需要分析的仅限于滑石等可能有石棉混入的 表A 括1000ppm) 矿物原料 ― 部分偶氮染料/颜料(生成特定胺) 未有意添加 EU REACH法规 AnnexⅩⅦ 未有意添加,且镉含量不超过 镉及其化合物 需要 2011/65/EU(EU RoHS2指令) 5ppm(不包括5ppm) 未有意添加,且六价铬含量不超过 六价铬化合物 需要 2011/65/EU(EU RoHS2指令) 100ppm(不包括100ppm) 未有意添加,且铅含量不超过100ppm(不包 铅及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm) 未有意添加,且汞含量不超过100ppm(不包 汞及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm) 未有意添加,且PBB含量不超过100ppm(不 多溴联苯类(PBB类) 需要 2011/65/EU(EU RoHS2指令) 包括100ppm) 未有意添加,且PBDE含量不超过100ppm(不 2011/65/EU(EU RoHS2指令) 多溴联苯醚类(PBDE类) 需要 包括100ppm) 包括十溴联苯醚 蒙特利尔议定书 臭氧层破坏物质 未有意添加 ― 同时禁止在制造工序中使用 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸(2-乙基己基)酯(DEHP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸二正丁酯(DBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸丁基苄酯(BBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸二异丁酯(DIBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 斯德哥爾摩公約 Annex A 多氯联苯类(PCB类) 未有意添加 ― 第一种特定化学物质(日本 化学物质的审 查及制造等的规制法)(以下简称化审法) 多氯三联苯类(PCT类) 未有意添加 ― EU REACH法规 AnnexⅩⅦ ― 多氯萘(氯原子数大于等于2) 未有意添加 化审法第一种特定化学物质 放射性物质 未有意添加 ― 使用放射性同位素的分析仪器除外 ― 斯德哥爾摩公約 Annex A 短链氯化石蜡(C10-C13) 未有意添加 化审法第一种特定化学物质 EU REACH法规 AnnexⅩⅦ 三丁基氧化锡(TBTO) 未有意添加 ― 化审法第一种特定化学物质 未有意添加,且含量不超过25ppb(不包括 全氟辛酸(PFOA)和其盐类及其PFOA的相关物 POPs公约 Annex A 25ppb)(PFOA相关物质不超过1000ppb) ― 质 EU POPs规则 附属书1 (不包括1000ppb) 未有意添加,且含量不超过25ppb(不包括 全氟乙基磺酸(PFHxS)及其盐类及PFHxS 相关 25ppb)(PFHxS相关物质不超过1000ppb) ― POPs公约 Annex A 物质 (不包括1000ppb) 三取代有机锡化合物 EU REACH法规 AnnexⅩⅦ 未有意添加 ― (包括TBT类、TPT类)(注1) -
Control Substance List
Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine -
Nove Psihoaktivne Tvari
TRENUTNO AKTIVNI SMART SHOPOVI U RH SINTETSKI KANABINOIDI TRIPTAMINI TOBACOO I VIDEOTEKA - ČAKOVEC Tvari koji oponašaju učinke kanabisa. Tvari koje izazivaju halucinogeno djelovanje. ■■Ulica kralja Tomislava 4 Vežu se na kanabinoidne receptore CB1 i CB2. SEKS SHOP I SMART SHOP - KOPRIVNICA ■■Ivana Generalić 3 HEAD SHOP SHOP - OSIJEK ■■Strossmayerova 39 SMART SHOP ART-MUSIK - PULA z primjeri kemijskih naziva: 5-MeO-DMT, 5-MeO-AMT, DPT ■■Zadarska 3 ■ IGROW SHOP - RIJEKA ■ izazivaju halucinogeno djelovanje; ■■Blaža Polića 5 najčešće se konzumiraju pušenjem, oralno, ušmrkavanjem, inhalacijom, injektiranjem SMART SHOP” - SLAVONSKI BROD ■■mijenjaju doživljaj realnosti, uzrokuju strah, ■■Starčevića 23 tjeskobu, povećanje srčanog pulsa IGROW SHOP - SPLIT ■■Mihovilova širina 19 z primjeri kemijskih naziva: JWH-018, NOVE JWH-250, JWH-122, AM-2201, RCS-04, SMART SHOP - ŠIBENIK DRUGI ■■Zagrebačka 9 UR-144, 5F UR-144, 5Cl UR-144 PSIHOAKTIVNE SNAIL SMART SHOP - ZADAR Tvari koje ne pripadaju niti jednoj od ■■mješavina bilja koja se reklamira kao “egzotični ■■Stomorica 2 navedenih skupina. Pojavljuju se u obliku mirisi” ili osvježivači prostora uz čestu TVARI SMART SHOP - ZAGREB napomenu kako nisu za konzumaciju tableta, praha, biljnih pripravaka te ■ ■ Maradona smart shop Tkalčićeva 12 ■■sadrže sintetske kanabinoide pa se uzrokuju različite psihoaktivne učinke. ■Grow shopzg Ilica 93 ■ pušenjem postižu učinci slični kanabisu ■■King size head shop Petrinjska 4 ■ ■■Smart shop Apoteka Selska 215 ■ imaju psihoaktivni učinak sličan učinku ■■Nail grow shop -
Comprehensive Multi-Analytical Screening Of
COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA, -
Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.